Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Determinants of fibrosis progression and regression in NASH
Detlef Schuppan, Rambabu Surabattula, Xiaoyu Wang
Journal of Hepatology (2017) Vol. 68, Iss. 2, pp. 238-250
Closed Access | Times Cited: 419

Showing 1-25 of 419 citing articles:

Mechanisms and disease consequences of nonalcoholic fatty liver disease
Rohit Loomba, Scott L. Friedman, Gerald I. Shulman
Cell (2021) Vol. 184, Iss. 10, pp. 2537-2564
Open Access | Times Cited: 1254
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Maurizio Parola, Massimo Pinzani
Molecular Aspects of Medicine (2018) Vol. 65, pp. 37-55
Open Access | Times Cited: 899
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Natascha Roehlen, Émilie Crouchet, Thomas F. Baumert
Cells (2020) Vol. 9, Iss. 4, pp. 875-875
Open Access | Times Cited: 852
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Konstantin Kazankov, Simon Mark Dahl Baunwall, Karen Louise Thomsen, et al.
Nature Reviews Gastroenterology & Hepatology (2018) Vol. 16, Iss. 3, pp. 145-159
Closed Access | Times Cited: 746
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 655
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven Francque, Pierre Bédossa, Vlad Ratziu, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 17, pp. 1547-1558
Open Access | Times Cited: 483
Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases
Boris Hinz, David Lagares
Nature Reviews Rheumatology (2019) Vol. 16, Iss. 1, pp. 11-31
Open Access | Times Cited: 464
Liver fibrosis: Direct antifibrotic agents and targeted therapies
Detlef Schuppan, Muhammad Ashfaq–Khan, Ai Ting Yang, et al.
Matrix Biology (2018) Vol. 68-69, pp. 435-451
Closed Access | Times Cited: 374
Update to the Society of Radiologists in Ultrasound Liver Elastography Consensus Statement
R. Graham Barr, Stephanie R. Wilson, Deborah J. Rubens, et al.
Radiology (2020) Vol. 296, Iss. 2, pp. 263-274
Closed Access | Times Cited: 351
Adaptive immunity: an emerging player in the progression of NAFLD
Salvatore Sutti, Emanuele Albano
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 17, Iss. 2, pp. 81-92
Open Access | Times Cited: 307
Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis
Geoff Farrell, Jörn M. Schattenberg, Isabelle Leclercq, et al.
Hepatology (2018) Vol. 69, Iss. 5, pp. 2241-2257
Open Access | Times Cited: 277
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Romina Lomonaco, Eddison Godinez Leiva, Fernando Bril, et al.
Diabetes Care (2020) Vol. 44, Iss. 2, pp. 399-406
Open Access | Times Cited: 250
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Kalliopi Pafili, Michael Roden
Molecular Metabolism (2020) Vol. 50, pp. 101122-101122
Open Access | Times Cited: 240
Non-alcoholic fatty liver disease: A patient guideline
Sven Francque, Giulio Marchesini, Achim Kautz, et al.
JHEP Reports (2021) Vol. 3, Iss. 5, pp. 100322-100322
Open Access | Times Cited: 207
Nonalcoholic Steatohepatitis Is Associated With Liver‐Related Outcomes and All‐Cause Mortality in Chronic Hepatitis B
Hannah Choi, Willem Pieter Brouwer, Wayel M.R. Zanjir, et al.
Hepatology (2019) Vol. 71, Iss. 2, pp. 539-548
Closed Access | Times Cited: 169
TGF‐β as a driver of fibrosis: physiological roles and therapeutic opportunities
Erine H. Budi, Johanna Schaub, Martin Decaris, et al.
The Journal of Pathology (2021) Vol. 254, Iss. 4, pp. 358-373
Open Access | Times Cited: 169
Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression
Alessandra Caligiuri, Alessandra Gentilini, Mirella Pastore, et al.
Cells (2021) Vol. 10, Iss. 10, pp. 2759-2759
Open Access | Times Cited: 167
Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment
Leen Heyens, Dana Busschots, Ger H. Koek, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 163
Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019
Pegah Golabi, James M. Paik, Saleh A. Alqahtani, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 4, pp. 795-809
Closed Access | Times Cited: 163
Metabolic Inflammation—A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?
Nadine Gehrke, Jörn M. Schattenberg
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1929-1947.e6
Closed Access | Times Cited: 161
Collagen biology and non‐invasive biomarkers of liver fibrosis
M.A. Karsdal, Samuel J. Daniels, Signe Holm Nielsen, et al.
Liver International (2020) Vol. 40, Iss. 4, pp. 736-750
Open Access | Times Cited: 160
Immunological mechanisms and therapeutic targets of fatty liver diseases
Hua Wang, Wajahat Z. Mehal, Laura E. Nagy, et al.
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 1, pp. 73-91
Open Access | Times Cited: 155
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. s49-s67.2
Open Access | Times Cited: 153
An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease
Ke Pei, Ting Gui, Dongfang Kan, et al.
BioMed Research International (2020) Vol. 2020, pp. 1-12
Open Access | Times Cited: 148
Management of non-alcoholic fatty liver disease
Maria Letizia Petroni, Lucia Brodosi, Elisabetta Bugianesi, et al.
BMJ (2021), pp. m4747-m4747
Open Access | Times Cited: 148
Page 1 - Next Page

Scroll to top